Lv4
446 积分 2021-09-23 加入
SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition
16小时前
已完结
Pan-cancer analysis reveals homologous recombination deficiency score as a predictive marker for immunotherapy responders
5天前
已完结
Exploring the Prognostic and Predictive Impact of Genomic Loss of Heterozygosity and Homologous Recombination Deficiency Alterations in Patients With Metastatic Colorectal Cancer
5天前
已关闭
Homologous Recombination Deficiency Is Associated with Shorter Survival in Colorectal Cancer Patients
5天前
已完结
KRAS inhibitors: resistance drivers and combinatorial strategies
9天前
已完结
Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT
12天前
已关闭
Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer
14天前
已完结
Benmelstobart plus anlotinib in patients with EGFR-positive advanced NSCLC after failure of EGFR TKIs therapy: a phase I/II study
19天前
已完结
Circulating tumor DNA Clearance as a Predictive Biomarker of Pathologic Complete Response in Patients with Solid Tumors Treated with Neoadjuvant Immune-Checkpoint Inhibitors: a Systematic Review and Meta-Analysis
19天前
已完结
Utilizing Combined Circulating Tumor DNA and Tumor Markers to Evaluate Neoadjuvant Therapy Response and Predict Recurrence in Patients with Locally Advanced Gastric Cancer
19天前
已完结
皖公网安备34019202002308
